Phase 1 clinical trial shows the safety, feasibility of CAR-M cell therapy for solid tumors

Preliminary results from Penn Medicine in an ongoing first-ever human clinical trial examining the safety, tolerability, and feasibility of macrophage chimeric antigen (CAR-M) have helped demonstrate the feasibility of this innovative immunotherapy, which advances the scientific groundbreaking discovery of CAR T-cell therapy. In Penn- for Solid Cancer Tumors and presents a promising new strategy in … Read more

New combination immune therapy for cancer is effective and has fewer side effects, study finds

Google “chemotherapy side effects” and the results abound. Nausea, anemia, infection, fertility problems, kidney problems, mouth sores. And the list goes on and on. The inevitable downside of cancer treatment always seems to be a decrease in their quality of life. But a new study at Northwestern Medicine found that the new combination immunotherapy not … Read more

Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma

Early results from the Clinical Trials Alliance in Oncology randomized clinical trials of adults with relapsing multiple myeloma in frontline treatment of lenalidomide show that adding ixazomib (Ninlaro┬«) to pomalidomide and dexamethasone as part of second-line treatment prolonged the time patients lived before being treated. . Exacerbation of disease (progression-free survival) compared to patients who … Read more

Wistar announces initiation of Phase 2 clinical study of VK-2019 in patients with advanced head and neck cancer

The Wistar Institute announces the start of a phase II clinical study of VK-2019 in patients with advanced Epstein-Barr Carcinoma (EBV)-nasopharyngeal carcinoma (NPC) and lymphoma. The study, which is being led by researchers at Stanford University School of Medicine, will include patients who have recurred, progressed after standard treatment, or who have not responded to … Read more

LIVE-AIR trial demonstrates efficacy of Lenzilumab for treatment of COVID patients with decreased oxygen saturation

The novel coronavirus 2019 (COVID-19) pandemic was caused by a new coronavirus, i.e., severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The RNA virus causes mild to severe symptoms and has a high transmission rate. In severe infection, patients often have a highly inflammatory response, which has been associated with morbidity and mortality due to COVID-19 disease. … Read more